The role of hepatic cytochrome P-450 in sepsis

International Journal of Clinical and Experimental Medicine

Volumn 2, Issue 3, 2009, Pages 203-211

  Jacob, Asha ^a   Zhou, Mian ^a   Wu, Rongqian ^a   Wang, Ping ^a  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

CYP enzymes; Cytochrome P 450; Hepatic dysfunction; Liver; Sepsis

Indexed keywords

CYTOCHROME P450; HEXOBARBITAL; PHENAZONE; THEOPHYLLINE;

DISEASE SEVERITY; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; INJURY; LIVER DISEASE; MORBIDITY; MORTALITY; NONHUMAN; PROTEIN FUNCTION; REVIEW; SEPSIS; SEPTIC SHOCK;

EID: 74549186958     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. D.R. Nelson, Cytochrome P450 and the individuality of species, Arch Biochem Biophys 369 (1999) 1-10.
2. J.F. Wang, C.C. Zhang, K.C. Chou, D.Q. Wei, Structure of cytochrome p450s and personalized drug, Curr Med Chem 16 (2009) 232-244.
3. P. De Paepe, F.M. Belpaire, W.A. Buylaert, Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock, Clin Pharmacokinet 41 (2002) 1135-1151.
4. J.H. Crawford, S. Yang, M. Zhou, H.H. Simms, P. Wang, Down-regulation of hepatic CYP1A2 plays an important role in inflammatory responses in sepsis, Crit Care Med 32 (2004) 502-508.
5. M. Zhou, S.R. Maitra, P. Wang, The potential role of transcription factor aryl hydrocarbon receptor in downregulation of hepatic cytochrome P-450 during sepsis, Int J Mol Med 21 (2008) 423-428.
6. R. Wu, X. Cui, W. Dong, M. Zhou, H.H. Simms, P. Wang, Suppression of hepatocyte CYP1A2 expression by Kupffer cells via AhR pathway: the central role of proinflammatory cytokines, Int J Mol Med 18 (2006) 339-346.
7. S.H. Lee, S.M. Lee, Suppression of hepatic cytochrome p450-mediated drug metabolism during the late stage of sepsis in rats, Shock 23 (2005) 144-149.
8. A.E. Baue, Sepsis research: what did we do wrong? What would Semmelweis do today? Shock 16 (2001) 1-8.
9. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-Rodriguez, J.S. Steingrub, G.E. Garber, J.D. Helterbrand, E.W. Ely, C.J. Fisher, Jr., Efficacy and safety of recombinant human activated protein C for severe sepsis, N Engl J Med 344 (2001) 699-709.
10. G.S. Martin, D.M. Mannino, S. Eaton, M. Moss, The epidemiology of sepsis in the United States from 1979 through 2000, N Engl J Med 348 (2003) 1546-1554.
11. G. van den Berghe, P. Wouters, F. Weekers, C. Verwaest, F. Bruyninckx, M. Schetz, D. Vlasselaers, P. Ferdinande, P. Lauwers, R. Bouillon, Intensive insulin therapy in the critically ill patients, N Engl J Med 345 (2001) 1359-1367.
12. R.S. Hotchkiss, I.E. Karl, The pathophysiology and treatment of sepsis, N Engl J Med 348 (2003) 138-150.
13. C. Oberholzer, A. Oberholzer, M. Clare-Salzler, L.L. Moldawer, Apoptosis in sepsis: a new target for therapeutic exploration, Faseb J 15 (2001) 879-892.
14. K.J. Tracey, The inflammatory reflex, Nature 420 (2002) 853-859.
15. N.C. Riedemann, R.F. Guo, P.A. Ward, Novel strategies for the treatment of sepsis, Nat Med 9 (2003) 517-524.
16. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M.R. Pinsky, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care, Crit Care Med 29 (2001) 1303-1310.
17. M.A. West, W. Heagy, Endotoxin tolerance: A review, Crit Care Med 30 (2002) S64-S73.
18. I.H. Chaudry, Sepsis: lessons learned in the last century and future directions, Arch Surg 134 (1999) 922-929.
19. E.A. Deitch, Animal models of sepsis and shock: a review and lessons learned, Shock 9 (1998) 1-11.
20. M.P. Fink, S.O. Heard, Laboratory models of sepsis and septic shock, J Surg Res 49 (1990) 186-196.
21. S.M. Opal, The clinical relevance of endotoxin in human sepsis: a critical analysis, J Endotoxin Res 8 (2002) 473-476.
22. H. Wang, M. Yu, M. Ochani, C.A. Amella, M. Tanovic, S. Susarla, J.H. Li, H. Wang, H. Yang, L. Ulloa, Y. Al-Abed, C.J. Czura, K.J. Tracey, Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation, Nature 421 (2003) 384-388.
23. E.S. Van Amersfoort, T.J. Van Berkel, J. Kuiper, Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock, Clin Microbiol Rev 16 (2003) 379-414.
24. K.W. Tinsley, M.H. Grayson, P.E. Swanson, A.M. Drewry, K.C. Chang, I.E. Karl, R.S. Hotchkiss, Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells, J Immunol 171 (2003) 909-914.
25. D.G. Remick, G.R. Bolgos, J. Siddiqui, J. Shin, J.A. Nemzek, Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days, Shock 17 (2002) 463-467.
26. B. Zingarelli, M. Sheehan, P.W. Hake, M. O'Connor, A. Denenberg, J.A. Cook, Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways, J Immunol 171 (2003) 6827-6837.
27. C.S. Chung, G.Y. Song, J. Lomas, H.H. Simms, I.H. Chaudry, A. Ayala, Inhibition of Fas/Fas ligand signaling improves septic survival: differential effects on macrophage apoptotic and functional capacity, J Leukoc Biol 74 (2003) 344-351.
28. L.W. Dong, L.L. Wu, Y. Ji, M.S. Liu, Impairment of the ryanodine-sensitive calcium release channels in the cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis, Shock 16 (2001) 33-39.
29. D.G. Remick, D.R. Call, S.J. Ebong, D.E. Newcomb, P. Nybom, J.A. Nemzek, G.E. Bolgos, Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality, Crit Care Med 29 (2001) 473-481.
30. P. Wang, I.H. Chaudry, Mechanism of hepatocellular dysfunction during hyperdynamic sepsis, Am J Physiol 270 (1996) R927-938.
31. A. Ayala, C.S. Chung, J.L. Lomas, G.Y. Song, L.A. Doughty, S.H. Gregory, W.G. Cioffi, B.W. LeBlanc, J. Reichner, H.H. Simms, P.S. Grutkoski, Shock-induced neutrophil mediated priming for acute lung injury in mice: divergent effects of TLR-4 and TLR-4/FasL deficiency, Am J Pathol 161 (2002) 2283-2294.
32. H. Yang, M. Ochani, J. Li, X. Qiang, M. Tanovic, H.E. Harris, S.M. Susarla, L. Ulloa, H. Wang, R. DiRaimo, C.J. Czura, H. Wang, J. Roth, H.S. Warren, M.P. Fink, M.J. Fenton, U. Andersson, K.J. Tracey, Reversing established sepsis with antagonists of endogenous high-mobility group box 1, Proc Natl Acad Sci U S A 101 (2004) 296-301.
33. K.A. Wichterman, A.E. Baue, I.H. Chaudry, Sepsis and septic shock - a review of laboratory models and a proposal, J Surg Res 29 (1980) 189-201.
34. S. Yang, W.G. Cioffi, K.I. Bland, I.H. Chaudry, P. Wang, Differential alterations in systemic and regional oxygen delivery and consumption during the early and late stages of sepsis, J Trauma 47 (1999) 706-712.
35. S. Yang, C.S. Chung, A. Ayala, I.H. Chaudry, P. Wang, Differential alterations in cardiovascular responses during the progression of polymicrobial sepsis in the mouse, Shock 17 (2002) 55-60.
36. C.S. Chung, S. Yang, G.Y. Song, J. Lomas, P. Wang, H.H. Simms, I.H. Chaudry, A. Ayala, Inhibition of Fas signaling prevents hepatic injury and improves organ blood flow during sepsis, Surgery 130 (2001) 339-345.
37. P. Wang, Z.F. Ba, I.H. Chaudry, Hepatocellular dysfunction occurs earlier than the onset of hyperdynamic circulation during sepsis, Shock 3 (1995) 21-26.
38. P. Wang, Z.F. Ba, I.H. Chaudry, Hepatic extraction of indocyanine green is depressed early in sepsis despite increased hepatic blood flow and cardiac output, Arch Surg 126 (1991) 219-224.
39. P. Wang, M. Zhou, M.W. Rana, Z.F. Ba, I.H. Chaudry, Differential alterations in microvascular perfusion in various organs during early and late sepsis, Am J Physiol 263 (1992) G38-43.
40. P. Wang, Z.F. Ba, I.H. Chaudry, Mechanism of hepatocellular dysfunction during early sepsis. Key role of increased gene expression and release of proinflammatory cytokines tumor necrosis factor and interleukin-6, Arch Surg 132 (1997) 364-369; discussion 369-370.
41. S. Yang, M. Zhou, D.E. Fowler, P. Wang, Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines, Crit Care Med 30 (2002) 2729-2735.
42. D.J. Koo, I.H. Chaudry, P. Wang, Kupffer cells are responsible for producing inflammatory cytokines and hepatocellular dysfunction during early sepsis, J Surg Res 83 (1999) 151-157.
43. P. Wang, A. Ayala, Z.F. Ba, M. Zhou, M.M. Perrin, I.H. Chaudry, Tumor necrosis factor-alpha produces hepatocellular dysfunction despite normal cardiac output and hepatic microcirculation, Am J Physiol 265 (1993) G126-132.
44. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, D.W. Nebert, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6 (1996) 1-42.
45. P.Y. Cheng, E.T. Morgan, Hepatic cytochrome P450 regulation in disease states, Curr Drug Metab 2 (2001) 165-183.
46. M. Fuchs, Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges, Am J Physiol Gastrointest Liver Physiol 284 (2003) G551-557.
47. W.M. Lee, Drug-induced hepatotoxicity, N Engl J Med 349 (2003) 474-485.
48. M. Negishi, T. Uno, T.A. Darden, T. Sueyoshi, L.G. Pedersen, Structural flexibility and functional versatility of mammalian P450 enzymes, Faseb J 10 (1996) 683-689.
49. J.A. Peterson, S.E. Graham, A close family resemblance: the importance of structure in understanding cytochromes P450, Structure 6 (1998) 1079-1085.
50. S. Rendic, F.J. Di Carlo, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors, Drug Metab Rev 29 (1997) 413-580.
51. A.B. Rifkind, C. Lee, T.K. Chang, D.J. Waxman, Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes, Arch Biochem Biophys 320 (1995) 380-389.
52. G. Duester, Involvement of alcohol dehydrogenase, short-chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis, Biochemistry 35 (1996) 12221-12227.
53. D.R. Harder, W.B. Campbell, R.J. Roman, Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone, J Vasc Res 32 (1995) 79-92.
54. P. Anzenbacher, E. Anzenbacherova, Cytochromes P450 and metabolism of xenobiotics, Cell Mol Life Sci 58 (2001) 737-747.
55. S.N. de Wildt, G.L. Kearns, J.S. Leeder, J.N. van den Anker, Cytochrome P450 3A: ontogeny and drug disposition, Clin Pharmacokinet 37 (1999) 485-505.
56. M. Spatzenegger, Y. Horsmans, R.K. Verbeeck, Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats, Pharmacol Toxicol 86 (2000) 71-77.
57. R. Orlando, P. Piccoli, S. De Martin, R. Padrini, M. Floreani, P. Palatini, Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function, Clin Pharmacol Ther 75 (2004) 80-88.
58. E.T. Morgan, Regulation of cytochromes P450 during inflammation and infection, Drug Metab Rev 29 (1997) 1129-1188.
59. S.C. Piscitelli, W.G. Reiss, W.D. Figg, W.P. Petros, Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations, Clin Pharmacokinet 32 (1997) 368-381.
60. J.A. Carcillo, L. Doughty, D. Kofos, R.F. Frye, S.S. Kaplan, H. Sasser, G.J. Burckart, Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure, Intensive Care Med 29 (2003) 980-984.
61. D.S. McKindley, J. Boulet, K. Sachdeva, P. Wang, C. Chichester, Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide, Shock 17 (2002) 199-204.
62. A.O. Oyekan, The suppression by lipopolysaccharide of cytochrome P450-dependent renal vasodilation in the rat is mediated by nitric oxide, Eur J Pharmacol 277 (1995) 123-132.
63. M. Monshouwer, R.A. McLellan, E. Delaporte, R.F. Witkamp, A.S. van Miert, K.W. Renton, Differential effect of pentoxifylline on lipopolysaccharide- induced downregulation of cytochrome P450, Biochem Pharmacol 52 (1996) 1195-1200.
64. H. Iber, M.B. Sewer, T.B. Barclay, S.R. Mitchell, T. Li, E.T. Morgan, Modulation of drug metabolism in infectious and inflammatory diseases, Drug Metab Rev 31 (1999) 29-41.
65. S.I. Shedlofsky, B.C. Israel, C.J. McClain, D.B. Hill, R.A. Blouin, Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism, J Clin Invest 94 (1994) 2209-2214.
66. E.T. Morgan, Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab Dispos 29 (2001) 207-212.
67. Z. Abdel-Razzak, P. Loyer, A. Fautrel, J.C. Gautier, L. Corcos, B. Turlin, P. Beaune, A. Guillouzo, Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture, Mol Pharmacol 44 (1993) 707-715.
68. J. Muntane-Relat, J.C. Ourlin, J. Domergue, P. Maurel, Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture, Hepatology 22 (1995) 1143-1153.
69. E.T. Morgan, Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin, Mol Pharmacol 36 (1989) 699-707.
70. R. Bertini, M. Bianchi, A. Erroi, P. Villa, P. Ghezzi, Dexamethasone modulation of in vivo effects of endotoxin, tumor necrosis factor, and interleukin-1 on liver cytochrome P-450, plasma fibrinogen, and serum iron, J Leukoc Biol 46 (1989) 254-262.
71. C.W. Barker, J.B. Fagan, D.S. Pasco, Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes, J Biol Chem 267 (1992) 8050-8055.
72. K. Sujita, F. Okuno, Y. Tanaka, Y. Hirano, Y. Inamoto, S. Eto, M. Arai, Effect of interleukin 1 (IL-1) on the levels of cytochrome P-450 involving IL-1 receptor on the isolated hepatocytes of rat, Biochem Biophys Res Commun 168 (1990) 1217-1222.
73. Y. Fukuda, N. Ishida, T. Noguchi, A. Kappas, S. Sassa, Interleukin-6 down regulates the expression of transcripts encoding cytochrome P450 IA1, IA2 and IIIA3 in human hepatoma cells, Biochem Biophys Res Commun 184 (1992) 960-965.
74. C.V. Godellas, J.F. Williams, P.J. Fabri, Mixed-function oxidase activity in sepsis, J Surg Res 59 (1995) 783-786.
75. K. Sachdeva, B. Yan, C.O. Chichester, Lipopolysaccharide and cecal ligation/puncture differentially affect the subcellular distribution of the pregnane X receptor but consistently cause suppression of its target genes CYP3A, Shock 19 (2003) 469-474.
76. W. Ertel, M.H. Morrison, P. Wang, Z.F. Ba, A. Ayala, I.H. Chaudry, The complex pattern of cytokines in sepsis. Association between prostaglandins, cachectin, and interleukins, Ann Surg 214 (1991) 141-148.
77. T.E. Nicholson, K.W. Renton, Role of cytokines in the lipopolysaccharide-evoked depression of cytochrome P450 in the brain and liver, Biochem Pharmacol 62 (2001) 1709-1717.
78. N. Milosevic, H. Schawalder, P. Maier, Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes, Eur J Pharmacol 368 (1999) 75-87.
79. J.A. Carcillo, K.R. Korzekwa, G.S. Jones, R.A. Parise, D.G. Gillespie, M.J. Whalen, P.M. Kochanek, R.A. Branch, C.K. Kost, Jr., The cytochrome P450 suicide inhibitor, 1-aminobenzotriazole, sensitizes rats to zymosan-induced toxicity, Res Commun Mol Pathol Pharmacol 102 (1998) 57-68.
80. B.G. Harbrecht, R.F. Frye, M.S. Zenati, R.A. Branch, A.B. Peitzman, Cytochrome P-450 activity is differentially altered in severely injured patients, Crit Care Med 33 (2005) 541-546.
81. A.L. Baker, A.N. Kotake, D.A. Schoeller, Clinical utility of breath tests for the assessment of hepatic function, Semin Liver Dis 3 (1983) 318-329.
82. P. Honkakoski, M. Negishi, Regulation of cytochrome P450 (CYP) genes by nuclear receptors, Biochem J 347 (2000) 321-337.
83. D.J. Waxman, P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR, Arch Biochem Biophys 369 (1999) 11-23.
84. H. Greschik, D. Moras, Structure-activity relationship of nuclear receptor-ligand interactions, Curr Top Med Chem 3 (2003) 1573-1599.
85. M. Beato, P. Herrlich, G. Schutz, Steroid hormone receptors: many actors in search of a plot, Cell 83 (1995) 851-857.
86. D.J. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, R.M. Evans, The nuclear receptor superfamily: the second decade, Cell 83 (1995) 835-839.
87. B.M. Forman, J. Chen, R.M. Evans, The peroxisome proliferator-activated receptors: ligands and activators, Ann N Y Acad Sci 804 (1996) 266-275.
88. C. Handschin, U.A. Meyer, Induction of drug metabolism: the role of nuclear receptors, Pharmacol Rev 55 (2003) 649-673.
89. O. Hankinson, The aryl hydrocarbon receptor complex, Annu Rev Pharmacol Toxicol 35 (1995) 307-340.
90. E.A. Roberts, P.A. Harper, J.M. Wong, Y. Wang, S. Yang, Failure of Ah receptor to mediate induction of cytochromes P450 in the CYP1 family in the human hepatoma line SK-Hep-1, Arch Biochem Biophys 384 (2000) 190-198.
91. K. Gradin, J. McGuire, R.H. Wenger, I. Kvietikova, M.L. fhitelaw, R. Toftgard, L. Tora, M. Gassmann, L. Poellinger, Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor, Mol Cell Biol 16 (1996) 5221-5231.
92. S. Tomita, C.J. Sinal, S.H. Yim, F.J. Gonzalez, Conditional disruption of the aryl hydrocarbon receptor nuclear translocator (Arnt) gene leads to loss of target gene induction by the aryl hydrocarbon receptor and hypoxia-inducible factor 1alpha, Mol Endocrinol 14 (2000) 1674-1681.
93. H. Reyes, S. Reisz-Porszasz, O. Hankinson, Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor, Science 256 (1992) 1193-1195.
94. M. Whitelaw, I. Pongratz, A. Wilhelmsson, J.A. Gustafsson, L. Poellinger, Ligand-dependent recruitment of the Arnt coregulator determines DNA recognition by the dioxin receptor, Mol Cell Biol 13 (1993) 2504-2514.
95. P. Coumailleau, L. Poellinger, J.A. Gustafsson, M.L. Whitelaw, Definition of a minimal domain of the dioxin receptor that is associated with Hsp90 and maintains wild type ligand binding affinity and specificity, J Biol Chem 270 (1995) 25291-25300.
96. M.L. Whitelaw, J. McGuire, D. Picard, J.A. Gustafsson, L. Poellinger, Heat shock protein hsp90 regulates dioxin receptor function in vivo, Proc Natl Acad Sci U S A 92 (1995) 4437-4441.
97. T.J. Carlson, R.E. Billings, Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450, Mol Pharmacol 49 (1996) 796-801.
98. P. Shieh, M. Zhou, D.A. Ornan, I.H. Chaudry, P. Wang, Upregulation of inducible nitric oxide synthase and nitric oxide occurs later than the onset of the hyperdynamic response during sepsis, Shock 13 (2000) 325-329.
99. Y. Minamiyama, S. Takemura, S. Imaoka, Y. Funae, Y. Tanimoto, M. Inoue, Irreversible inhibition of cytochrome P450 by nitric oxide, J Pharmacol Exp Ther 283 (1997) 1479-1485.